FIELD: biotechnology.
SUBSTANCE: invention refers to an immunomodulating multidomain vesicle and a material containing said vesicle. Method involves preparing an oil phase solution containing a first immunomodulating material which controls an immunosuppressive factor and a liquid oil. Then, a water-in-oil emulsion (W/O) is obtained by dispersing a first aqueous phase containing a second immunomodulating material, controlling the immunosuppressive factor in the oil phase solution. Further, the water-in-oil emulsion is mixed with the second aqueous solution to obtain a vesicle containing at least two liposomes, in contact and connected to each other, and an external wall of immunomodulating multidomain vesicle surrounding at least two liposomes.
EFFECT: invention widens the range of equipment.
14 cl, 44 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTIDOMAIN VESICLE COMPRISING AN IMMUNOSTIMULATING MATERIAL, A METHOD FOR PRODUCTION THEREOF AND AN IMMUNOMODULATING COMPOSITION THEREOF | 2018 |
|
RU2736639C1 |
| COMPOSITION OF LIPID VESICLES AND METHODS OF APPLICATION | 2011 |
|
RU2595872C2 |
| TOLL-LIKE RECEPTOR 7 OR 8 AGONIST AND CHOLESTEROL COMPLEX AND ITS USE | 2020 |
|
RU2790702C1 |
| PEGYLATED LIPOSOMES AND THEIR APPLICATION METHODS | 2017 |
|
RU2796539C2 |
| PHARMACEUTICAL COMPOSITION BASED ON PLGA FOR THE INDUCTION OF THE EFFECTIVE MUCOSAL IMMUNE RESPONSE | 2018 |
|
RU2742580C2 |
| METHOD AND COMPOSITION FOR OTITIS EXTERNA TREATMENT | 2010 |
|
RU2680137C2 |
| PYRIMIDINE COMPOUND | 2016 |
|
RU2759917C2 |
| LIPOSOMAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2734900C1 |
| LIPOSOMES WITH LIPIDS, HAVING PREFERRED VALUE OF PKA FOR RNA DELIVERY | 2011 |
|
RU2589503C2 |
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN | 2016 |
|
RU2732567C2 |
